International Stereotactic Radiosurgery Society

Become a member | Log In | Contact us

The ISRS webinar series began in 2016. We have already delivered over 60 webinars on intracranial and body SRS and from experts around around the world.

A video replay of each past webinar is available to ISRS members.

Next Webinars

March 10, 2020

Leptomeningeal metastases: an overview of a devastating diagnosis by Hany SOLIMAN, MD, FRCPC

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00 pm (Brisbane)

Leptomeningeal metastases is characterized by dissemination of cancer cells throughout the leptomeninges and/or cerebrospinal fluid. It is usually associated with a very poor prognosis. This webinar will review the incidence in different cancers, predictors of and varying patterns seen with leptomeningeal metastases in clinical practice. Novel therapies including targeted agents have shown some promise in improving outcomes and will be highlighted.

March 25, 2020

Hypofractionated Radiosurgery for Perioptic Lesions by Herwin SPECKTER, Medical Physicist

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00 pm (Brisbane)

Hypofractionated stereotactic radiosurgery (HFSRS) is getting attention as an alternative to single fraction SRS in the management of larger volumes or of lesion close to organs at risk. SRS treatment of lesions residing in direct contact or in close proximity to the optic pathway remains challenging in order to minimize the risk for radiation induced optic neuropathy (RION).
This talk will address a brief review of evidence in literature on HFSRS for perioptic lesions, including our experience, comparison to single fraction SRS, imaging for optic pathway, risk analysis for RION, assessment of the alpha/beta ratio of the optic pathway, possible optimization of fractionation regimens, comparison to recommendations given by QUANTEC, HyTEC, and AAPM TG 101 initiatives.

April 16, 2020

SRS/SRT of Atypical and Anaplastic Meningiomas by Elitsa ENCHEVA, MD, PhD, Professor

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00 pm (Brisbane)

The webinar will discuss: 1) the current WHO classification for meningioma and the incidence of the atypical and anaplastic meningioma and the treatment results according to it. 2) the treatment strategy for both atypical and anaplastic meningioma and the role of radiotherapy 3) the current evidence supporting EBRT, SRS and SRT implementation for atypical and anaplastic meninigiomas in adjuvant and recurrent settings

April 27, 2020

MR-guided radiotherapy: a game changer or all hype? by Alison TREE, MD (Res)

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00 pm (Brisbane)

MR-guided radiotherapy promises to revolutionise radiotherapy delivery. These systems bring the obvious benefits of improved soft-tissue definition, and the ability to monitor anatomy with cineMRI during beam-on. However, the more fundamental innovation is the ability to deliver daily adaptive replanning while the patient is on the bed, allowing us to, for the first time, adapt our radiation plan daily to account for anatomical changes. This has great potential, particularly in the ‘hard to treat’ cancers where dose escalation has previously been limited by proximity to OARs, and the need to cover a large margin for interfraction variability. Dr Tree will share the Royal Marsden/Institute of Cancer Research experience of MR-guided radiotherapy and suggest some areas where it will improve patient care in the future.